Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, Kumar P, Kumar R, Das P, Mitra G, Flevaud L, Ferreyra C, Remartinez D, Pece M, Palma PP.

Clin Infect Dis. 2011 Oct;53(7):e91-8. doi: 10.1093/cid/cir521.

PMID:
21890763
2.

Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.

Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili KD, Lima MA, Mitra G, Kumar D, Pandey K, Van Geertruyden JP, Boelaert M, Burza S.

Clin Infect Dis. 2015 Oct 15;61(8):1255-62. doi: 10.1093/cid/civ530. Epub 2015 Jun 30.

3.

Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M.

Clin Infect Dis. 2009 Jan 15;48(2):e16-22. doi: 10.1086/595710.

PMID:
19093811
4.

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, Balasegaram M, Das P.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2603. doi: 10.1371/journal.pntd.0002603. eCollection 2014. Erratum in: PLoS Negl Trop Dis. 2014 Apr;8(4):e2813. Balasegarem, Manica [corrected to Balasegaram, Manica].

5.

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.

Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.

Clin Infect Dis. 2011 Dec;53(12):e152-8. doi: 10.1093/cid/cir674. Epub 2011 Oct 19.

PMID:
22016502
6.

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).

Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Kumar S, Mitra G, Kumar R, Verma N, Das P.

PLoS Negl Trop Dis. 2014 Aug 7;8(8):e3053. doi: 10.1371/journal.pntd.0003053. eCollection 2014 Aug.

7.

Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?

Salih NA, van Griensven J, Chappuis F, Antierens A, Mumina A, Hammam O, Boulle P, Alirol E, Alnour M, Elhag MS, Manzi M, Kizito W, Zachariah R.

Trop Med Int Health. 2014 Feb;19(2):146-52. doi: 10.1111/tmi.12238. Epub 2014 Jan 17.

8.

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

Burza S, Sinha PK, Mahajan R, Sanz MG, Lima MA, Mitra G, Verma N, Das P.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2611. doi: 10.1371/journal.pntd.0002611. eCollection 2014.

9.

Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.

ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN.

Clin Infect Dis. 2008 Jun 1;46(11):1702-9. doi: 10.1086/587899.

PMID:
18419422
10.

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.

Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Oct;60(4):837-42. Epub 2007 Aug 7.

PMID:
17684055
11.

Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, Balasegaram M, Das P.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2536. doi: 10.1371/journal.pntd.0002536. eCollection 2014. Erratum in: PLoS Negl Trop Dis. 2014 Apr;8(4):e2813. Balsegaram, Manica [corrected to Balasegaram, Manica].

12.

Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India.

Goswami RP, Goswami RP, Basu A, Ray Y, Rahman M, Tripathi SK.

Am J Trop Med Hyg. 2017 Feb 8;96(2):285-291. doi: 10.4269/ajtmh.16-0432. Epub 2016 Nov 22.

PMID:
27879457
13.

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).

Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, Davidson RN.

J Infect. 1996 Mar;32(2):133-7.

PMID:
8708370
14.

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.

López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Cañavate C, Alvar J; Spanish HIV-Leishmania Study Group.

J Antimicrob Chemother. 2004 Mar;53(3):540-3. Epub 2004 Jan 22.

PMID:
14739148
15.

Liposomal amphotericin B for the treatment of visceral leishmaniasis.

Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J.

Clin Infect Dis. 2006 Oct 1;43(7):917-24. Epub 2006 Aug 28.

PMID:
16941377
16.

Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy.

Villanueva JL, Alarcón A, Bernabeu-Wittel M, Cordero E, Prados D, Regordán C, Alvar J.

Eur J Clin Microbiol Infect Dis. 2000 Oct;19(10):798-801.

PMID:
11117648
17.

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.

Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E.

Medicine (Baltimore). 2001 Jan;80(1):54-73.

18.
19.

Visceral leishmaniasis mimicking as second line anti retroviral therapy failure.

Yanamandra U, Jairam A, Shankar S, Negi R, Guleria B, Nair V.

Intern Med. 2011;50(22):2855-8. Epub 2011 Nov 15.

20.

Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.

Patole S, Burza S, Varghese GM.

Int J Infect Dis. 2014 Aug;25:204-6. doi: 10.1016/j.ijid.2014.02.015. Epub 2014 Jun 10.

Supplemental Content

Support Center